tirzepatide osa trial and Semaglutide: Impact on in Obesity Diabetes drug resolves sleep apnea

When examining a composite cardio outcomes endpoint (death from CV disease, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina), the ELIXA trial suggested that GLP-1s did not increase cardiovascular event risk (hazard ratio of 1.02)

The risk of kidney failure is much higher among individuals who already have existing problems with their kidneys

[3] Other common adverse effects reported during the clinical trials include back pain, upper respiratory tract infections, melanocyte naevus, decreased appetite, migraine, dizziness, weakness, fatigue, lethargy, sleepiness, hot flashes, abdominal pain, diarrhea, vomiting, flushing, development of warts, spots, and freckles, and itchy skin (between 1% and 10% of people)

Market positioning: Semaglutide is becoming more affordable with generics, whereas tirzepatide (by Eli Lilly) remains a premium, patented therapy

Akkermansia is notoriously difficult to deliver in supplement form because it is an anaerobic organism that dies on exposure to oxygen